KRAS drug and immunotherapy trial in pancreatic cancer reported 97% of patients reached surgery with clear margins. The trial enrolled about 30 patients per group and had no control arm or survival data yet.
Key points
97% reached surgery in the immunotherapy group.
Every surgery removed the tumour completely with clear margins.
Trial size was roughly 30 patients per group.
Sources
Sac-TMT cuts endometrial cancer progression risk by 41% in Phase III trial
Sac-TMT cut endometrial cancer progression risk by 41% versus chemotherapy in a Phase III trial. The trial involved women previously treated with chemotherapy and immunotherapy.
Key points
Sac-TMT reduced progression risk by 41% versus chemotherapy.
Phase III trial enrolled women previously treated with chemotherapy and immunotherapy.
Sources
- Original post
- medicalxpress.com - Linked in the post
MRG007 (CDH17 ADC) exposure comment and exatecan % of ADC AUC
MRG007 (CDH17 ADC) post critiques an exposure comment that uses ng/mL based on Cmax despite differing molecular weights (150,000 vs 435). It notes that exatecan exposure is high at 6% of ADC AUC, especially for a DAR4 ADC, and provides a replotted view in nM.
Key points
Molecular weights: 150,000 versus 435.
Exatecan exposure: 6% of ADC AUC for a DAR4 ADC.
Sources
ARTEMIS_011 data shows HR 0.33 vs gemcitabine_docetaxel
ARTEMIS_011 of Ris-Rez B7H3 ADC presented with a hazard ratio of 0.33 versus gemcitabine_docetaxel in relapsed osteosarcoma. The presentation was at the ESMO26 presidential symposium.
Key points
Presentation: promising data of ARTEMIS_011 of Ris-Rez B7H3 ADC in relapsed osteosarcoma.
Result: hazard ratio 0.33 over gemcitabine_docetaxel.
Sources
Ruzaltatug rezetecan vs chemotherapy – HERON-Lung01 interim analysis
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced NSCLC progressing after EGFR TKI therapy presented at ESMO2026 as an interim analysis of a randomised, open-label phase 3 trial in China. The study targets patients with EGFR-mutated advanced non-small-cell lung cancer who have progressed after EGFR tyrosine kinase inhibitor therapy.
Key points
Randomised, open-label, phase 3 trial.
Conducted in China.
Sources
- Original post
- spkl.io - Linked in the post
MASTERPLAN trial - phase 2 randomised study announced
MASTERPLAN is an open-label, phase 2, multicentre, randomised trial comparing perioperative chemotherapy plus stereotactic body radiotherapy versus perioperative chemotherapy alone in high-risk, localised pancreatic cancer. The post shares the trial title and design.
Key points
Trial name: MASTERPLAN
Design: open-label, phase 2, multicentre, randomised
Sources
Tarlatamab shows sustained survival benefit in SCLC
Tarlatamab shows sustained survival benefit in SCLC in long-term follow-up of the DeLLphi-304 trial. The results were presented at ESMO26 and the author calls for patient access.
Key points
Sustained survival benefits in relapsed-refractory SCLC
Long-term follow-up from the DeLLphi-304 trial presented at ESMO26
